Jfl Life Sciences Limited (NSE: JFLLIFE) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹45 Cr, it ranks #3,867 by market cap among the 6,197 Indian listed companies on FinBizNet, and #52 of 63 in Pharmaceuticals. At ₹13.50 (as of 16 Nov 2026), the share price is 12.3% below its 52-week high of ₹15.40 and 57.9% above its 52-week low of ₹8.55. The share price is down 0.4% over one year and up 3.9% over three months.
| Current Price | ₹13.50 |
|---|---|
| Market Cap | ₹45 Cr |
| NSE Symbol | JFLLIFE |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 7 |
| Return on Equity | 15.00% |
| Return on Assets | 7.46% |
| 52-Week Range | ₹8.55 – ₹15.40 |
| 1-Year Price Change | -0.4% |
| 3-Month Price Change | +3.9% |
| Beta (1Y) | -0.11 |
| Dividend Yield | 0.00% |
| Headquarters | Ahmedabad, Gujarat |
| Website | jfllifesciences.com |
| Revenue | ₹99 Cr |
|---|---|
| Net Profit | ₹5 Cr |
| Net Margin | 5.2% |
| EPS (Basic) | ₹1.28 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Jfl Life Sciences Limited reported revenue of ₹99 Cr in Q2 FY27, up 229.8% from ₹30 Cr in Q2 FY26 and up 788.7% from ₹11 Cr in Q1 FY27. It posted a net profit of ₹5 Cr for the quarter, against a net profit of ₹2 Cr in Q2 FY26 (up 159.1%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹11 Cr (Q1 FY27) to ₹99 Cr (Q2 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹99 Cr | ₹5 Cr | 5.2% |
| Q1 FY27 | ₹11 Cr | ₹1 Cr | 10.0% |
| Q4 FY26 | ₹63 Cr | ₹2 Cr | 2.6% |
| Q3 FY26 | ₹27 Cr | ₹2 Cr | 7.5% |
| Q2 FY26 | ₹30 Cr | ₹2 Cr | 6.6% |
| Q1 FY26 | ₹12 Cr | ₹1 Cr | 6.5% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 67.47% of Jfl Life Sciences Limited's shares as of Sept 2026, unchanged from Sept 2025.
JFL Life Sciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers beta lactam dry powder injections, beta lactam tablets and capsules in solid oral dosage form, oral rehydration solutions, and general tablets and capsules. It also exports its products to Africa, the Middle East, and CIS countries through merchant exporters. JFL Life Sciences Limited was incorporated in 2010 and is headquartered in Ahmedabad, India.
1. Pharmaceuticals Manufacturing-This segment manufactures and sells pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals Manufacturing-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Jfl Life Sciences Limited | ₹45 Cr | 7 | 15.00% | ₹99 Cr | -0.4% |
Listed by market capitalisation. Ratios are shown for context only.
Jfl Life Sciences Limited is trading at ₹13.50, with a market capitalisation of ₹45 Cr.
Jfl Life Sciences Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Jfl Life Sciences Limited has a P/E of 7 and a return on equity of 15.00%.
Jfl Life Sciences Limited is listed on the NSE under the symbol JFLLIFE.
Jfl Life Sciences Limited's share price is down 0.4% over one year and up 3.9% over three months. Its 52-week range is ₹8.55 to ₹15.40.
In Q2 FY27, Jfl Life Sciences Limited reported revenue of ₹99 Cr and net profit of ₹5 Cr, with basic EPS of ₹1.28 (standalone, parsed from the company's exchange filing).
Jfl Life Sciences Limited reported revenue of ₹99 Cr in Q2 FY27, up 229.8% from ₹30 Cr in Q2 FY26 and up 788.7% from ₹11 Cr in Q1 FY27.
Promoters held 67.47% of Jfl Life Sciences Limited's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.